Cistor 10 mg (Cisplatin) Injection

Introduction to Cistor 10 mg (Cisplatin) Injection

Cistor 10 mg, containing the active ingredient Cisplatin, is a platinum-based chemotherapy injection critical for treating metastatic testicular tumors, ovarian cancer, advanced bladder cancer, and non-small cell lung carcinoma (NSCLC). Manufactured by Eskayef Pharmaceuticals Ltd. and supplied globally by Saif Pharma, this cytotoxic agent disrupts cancer cell DNA replication, offering proven efficacy in combination and monotherapy regimens.

Key Indications & Therapeutic Benefits

• Testicular Cancer: Used in combination therapy post-surgery/radiotherapy for metastatic disease.
• Ovarian Cancer: Effective in combination with cyclophosphamide or as a secondary monotherapy for refractory cases.
• Bladder Cancer: Single-agent therapy for transitional cell bladder cancer unresponsive to surgery/radiation.
• Lung Cancer: Combined with paclitaxel for NSCLC in non-surgical candidates.
• Mechanism of Action: Forms DNA cross-links, blocking replication and inducing apoptosis in cancer cells.

Pharmacology & Pharmacokinetics

• Chemical Class: Platinum coordination compound (alkylating agent).
• Absorption: Administered intravenously (IV) for systemic delivery.
• Distribution: Binds to plasma proteins; accumulates in kidneys, liver, and tumors.
• Metabolism: Minimal hepatic metabolism; 90-95% excreted renally within 24 hours.
• Half-Life: Initial phase: 20-30 minutes; terminal phase: 58-73 hours due to tissue binding.

Recommended Dosage & Administration

• Testicular Cancer: 20 mg/m² IV daily for 5 days per cycle (combined with other agents).
• Ovarian Cancer:
  • Combination Therapy: 75–100 mg/m² IV every 4 weeks with cyclophosphamide.
  • Monotherapy: 100 mg/m² IV every 4 weeks for refractory cases.
• Bladder Cancer: 50–70 mg/m² IV every 3–4 weeks (adjust based on prior therapy).
• Lung Cancer: 75 mg/m² IV every 3 weeks with paclitaxel (135 mg/m²).
• Administration Guidelines:
  • IV Infusion: Administer slowly over 6–8 hours to reduce nephrotoxicity.
  • Hydration: Pre- and post-hydration with 1–2 liters of fluid to protect kidney function.
  • Avoid Aluminum: Use non-aluminum IV sets to prevent potency loss.

Drug Interactions & Precautions

• Nephrotoxic Drugs (e.g., Aminoglycosides): Increase kidney damage risk; avoid concurrent use.
• Ototoxic Agents (e.g., Loop Diuretics): Heighten hearing loss risk, especially with renal impairment.
• Anticonvulsants (e.g., Phenytoin): Cisplatin may reduce phenytoin levels; monitor serum levels.
• Antigout Medications: Adjust allopurinol/colchicine doses due to cisplatin-induced hyperuricemia.

Contraindications & Safety Warnings

• Renal Impairment: Contraindicated in pre-existing kidney dysfunction (serum creatinine >1.5 mg/dL).
• Hypersensitivity: Avoid in patients allergic to cisplatin or platinum compounds.
• Myelosuppression/Hearing Loss: Not recommended for patients with severe bone marrow suppression or pre-existing hearing deficits.

Common Side Effects

• Gastrointestinal: Severe nausea/vomiting (90%), diarrhea (10%).
• Renal: Cumulative nephrotoxicity (elevated creatinine, hypomagnesemia, hypokalemia).
• Hematologic: Anemia (25%), leukopenia (15%), thrombocytopenia (10%).
• Neurologic: Peripheral neuropathy (30%), ototoxicity (10-15%), seizures (rare).
• Other: Alopecia, electrolyte imbalances, anaphylactoid reactions.

Storage & Handling

• Storage: Store at 25°C in original packaging; avoid refrigeration and light exposure.
• Reconstitution: Use sterile diluents (e.g., saline); discard unused portions.
• Disposal: Follow cytotoxic waste protocols for vials/syringes.

Why Choose Cistor 10 mg from Saif Pharma?

Saif Pharma is a globally recognized distributor of oncology medications, delivering high-quality, affordable chemotherapy drugs to 60+ countries, including the USA, Canada, UAE, and India. Partnering with Eskayef Pharmaceuticals—a WHO-GMP-certified manufacturer—ensures rigorous quality control, making Cistor 10 mg a trusted choice for oncologists.

Manufacturer & Supplier Credentials

• Manufacturer: Eskayef Pharmaceuticals Ltd. – A leader under Bangladesh’s Transcom Group, producing globally compliant medicines since 1990.
• Supplier: Saif Pharma – Specializing in oncology since 2014, committed to reducing cancer mortality through accessible therapies.

Clinical Advantages of Cisplatin

• Broad Spectrum: Effective against multiple solid tumors.
• Synergy in Combination: Enhances efficacy of taxanes, cyclophosphamide, and other agents.
• Established Track Record: Over 40 years of clinical use with well-documented response rates (e.g., 70-80% in testicular cancer).

Patient Management Tips

• Pre-Medication: Administer 5-HT3 antagonists (e.g., ondansetron) and steroids to control nausea.
• Hydration Protocol: Ensure adequate IV fluids before/during infusion to mitigate renal toxicity.
• Monitoring:
  • Renal Function: Serum creatinine, BUN, and electrolytes (Mg²⁺, K⁺, Ca²⁺) before each cycle.
  • Audiometry: Baseline and periodic hearing tests for early detection of ototoxicity.

Overdose Management

Acute overdose may cause renal failure, deafness, myelosuppression, or death. No specific antidote exists; treatment is supportive (e.g., hemodialysis has limited efficacy due to high protein binding).

Conclusion

Cistor 10 mg (Cisplatin) Injection remains a cornerstone of chemotherapy for advanced cancers, balancing potent antitumor activity with manageable toxicity. For authentic, cost-effective access, trust Saif Pharma—your global partner in oncology care.